HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 294/6/L1217    most recent 00020.2008v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (7) Citing Articles via Google Scholar Google Scholar Articles by Hardie, W. D. Articles by Korfhagen, T. R. Search for Related Content PubMed PubMed Citation Articles by Hardie, W. D. Articles by Korfhagen, T. R.

EGF receptor tyrosine kinase inhibitors diminish transforming growth factor--induced pulmonary fibrosis

Divisions of ¹Pulmonary Medicine and ²Pulmonary Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio; ³Department of Environmental and Occupational Health, University of Pittsburgh, Pittsburgh, Pennsylvania; and ⁴Division of Pulmonary Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois

Submitted 10 January 2008 ; accepted in final form 15 April 2008

Transforming growth factor- (TGF-) is a ligand for the EGF receptor (EGFR). EGFR activation is associated with fibroproliferative processes in human lung disease and animal models of pulmonary fibrosis. We determined the effects of EGFR tyrosine kinase inhibitors gefitinib (Iressa) and erlotinib (Tarceva) on the development and progression of TGF--induced pulmonary fibrosis. Using a doxycycline-regulatable transgenic mouse model of lung-specific TGF- expression, we determined effects of treatment with gefitinib and erlotinib on changes in lung histology, total lung collagen, pulmonary mechanics, pulmonary hypertension, and expression of genes associated with synthesis of ECM and vascular remodeling. Induction in the lung of TGF- caused progressive pulmonary fibrosis over an 8-wk period. Daily administration of gefitinib or erlotinib prevented development of fibrosis, reduced accumulation of total lung collagen, prevented weight loss, and prevented changes in pulmonary mechanics. Treatment of mice with gefitinib 4 wk after the induction of TGF- prevented further increases in and partially reversed total collagen levels and changes in pulmonary mechanics and pulmonary hypertension. Increases in expression of genes associated with synthesis of ECM as well as decreases of genes associated with vascular remodeling were also prevented or partially reversed. Administration of gefitinib or erlotinib did not cause interstitial fibrosis or increases in lavage cell counts. Administration of small molecule EGFR tyrosine kinase inhibitors prevented further increases in and partially reversed pulmonary fibrosis induced directly by EGFR activation without inducing inflammatory cell influx or additional lung injury.

gefitinib; erlotinib; pulmonary hypertension

This article has been cited by other articles:

				R. M. Strieter and B. Mehrad New Mechanisms of Pulmonary Fibrosis Chest, November 1, 2009; 136(5): 1364 - 1370. [Abstract] [Full Text] [PDF]

				T. R. Korfhagen, T. D. Le Cras, C. R. Davidson, S. M. Schmidt, M. Ikegami, J. A. Whitsett, and W. D. Hardie Rapamycin Prevents Transforming Growth Factor-{alpha}-Induced Pulmonary Fibrosis Am. J. Respir. Cell Mol. Biol., November 1, 2009; 41(5): 562 - 572. [Abstract] [Full Text] [PDF]

				H. S. Deshmukh, A. McLachlan, J. J. Atkinson, W. D. Hardie, T. R. Korfhagen, M. Dietsch, Y. Liu, P. Y. P. Di, S. C. Wesselkamper, M. T. Borchers, et al. Matrix Metalloproteinase-14 Mediates a Phenotypic Shift in the Airways to Increase Mucin Production Am. J. Respir. Crit. Care Med., November 1, 2009; 180(9): 834 - 845. [Abstract] [Full Text] [PDF]

				E. L. Kramer, E. M. Mushaben, P. A. Pastura, T. H. Acciani, G. H. Deutsch, G. K. Khurana Hershey, T. R. Korfhagen, W. D. Hardie, J. A. Whitsett, and T. D. Le Cras Early Growth Response-1 Suppresses Epidermal Growth Factor Receptor-Mediated Airway Hyperresponsiveness and Lung Remodeling in Mice Am. J. Respir. Cell Mol. Biol., October 1, 2009; 41(4): 415 - 425. [Abstract] [Full Text] [PDF]

				Y. Xu, C. Saegusa, A. Schehr, S. Grant, J. A. Whitsett, and M. Ikegami C/EBP{alpha} is required for pulmonary cytoprotection during hyperoxia Am J Physiol Lung Cell Mol Physiol, August 1, 2009; 297(2): L286 - L298. [Abstract] [Full Text] [PDF]